BIOCRYST PHARMACEUTICALS INC (BCRX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for BIOCRYST PHARMACEUTICALS INC (BCRX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 61/100 — a percentile rank of BIOCRYST PHARMACEUTICALS INC’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.
| Market cap | $2.1B |
| P / S | 2.2× |
| EV / EBITDA | -8.8× |
| Gross margin | 97.8% |
| Operating margin | -33.3% |
| Net margin | -40.9% |
| Return on equity | 84.7% |
| ROIC | -147.1% |
| Revenue growth | 68.7% |
| Debt / equity | -1.8× |
| Dividend yield | 0.0% |
Is BIOCRYST PHARMACEUTICALS INC overvalued? P/S looks undervalued vs its 5-year range.
Independent of the events above — derived from BIOCRYST PHARMACEUTICALS INC’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact